Aurobindo Pharma has received US FDA approval for cephalexin tablets

Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy, and a number of other extremely committed professionals founded Aurobindo Pharma in 1986. The company started out in Pondicherry, India, in 1988–1989, operating a single unit that produced semi-synthetic penicillin (SSP). 1992 saw the public launch of Aurobindo Pharma, and in 1995 it began listing its shares on Indian stock exchanges. It is the industry leader in semi-synthetic penicillins and is present in several important therapeutic areas, including gastroenterology, anti-diabetics, neurosciences, cardiovascular, and anti-retrovirals. In the pharmaceutical sector, Aurobindo Pharma Limited has made a name for itself as a major force in India and around the world. Patients and medical professionals alike regard Aurobindo Pharma with confidence and trust because of its dedication to innovation and quality. The company is committed to enhancing universal access to reasonably priced healthcare solutions even as it grows its footprint in important global markets.

Aurobindo Pharma got the approval from USFDA:

The US Food and Drug Administration (USFDA) has given Aurobindo Pharma final approval to produce and distribute Cephalexin Tablets USP, 250 mg and 500 mg. These tablets are bioequivalent and therapeutically equivalent to Eli Lilly and Company’s reference listed drug (RLD), Keflet Tablets, 250 mg and 500 mg.

Cephalexin Tablets USP, 250 mg, and 500 mg have been given Competitive Generic Therapy (CGT) designation by Aurobindo Pharma, which makes them eligible for 180 days of shared generic drug exclusivity. It is anticipated that the product will debut in Q3 FY25. The prescribed microorganisms’ susceptible strains of infection can be treated with Cephalexin USP 250 mg and 500 mg tablets.

Aurobindo Pharma Ltd. stock is 1% up today:

Aurobindo Pharma Ltd.’s stock price is currently up more than 1% in the intraday segment at Rs. 1,455.55. Based on the US Food & Drug Administration’s (USFDA) approval to manufacture and market cephalexin tablets, the company is expected to see further growth in the coming days.

Conclusion:  The USFDA has approved Aurobindo Pharma Ltd. to produce and distribute cephalexin tablets, which is fantastic news for the company’s stock and revenue in the upcoming quarters.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.